Home › B-Cell Lymphoma
Pag-aaral pangklinika para sa B-Cell Lymphoma na nagre-recruit sa U.S.
67 pag-aaral para sa B-Cell Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY19 pag-aaral
- Houston, TX16 pag-aaral
- Chicago, IL12 pag-aaral
- Nashville, TN11 pag-aaral
- Philadelphia, PA11 pag-aaral
- Rochester, MN10 pag-aaral
- Milwaukee, WI9 pag-aaral
- Baldwin Park, CA9 pag-aaral
- Cleveland, OH8 pag-aaral
- Boston, MA8 pag-aaral
- Pittsburgh, PA7 pag-aaral
- Washington, DC7 pag-aaral
- Denver, CO7 pag-aaral
- Dallas, TX7 pag-aaral
- Salt Lake City, UT7 pag-aaral
- Charlotte, NC7 pag-aaral
- Columbus, OH7 pag-aaral
- Seattle, WA7 pag-aaral
- New Haven, CT6 pag-aaral
- Edison, NJ6 pag-aaral
- Aurora, CO6 pag-aaral
- Los Angeles, CA6 pag-aaral
- San Antonio, TX6 pag-aaral
- Omaha, NE5 pag-aaral
- Mountain View, CA5 pag-aaral
- Ann Arbor, MI5 pag-aaral
- Atlanta, GA5 pag-aaral
- Kansas City, MO5 pag-aaral
- St. Louis, MO5 pag-aaral
- Miami, FL4 pag-aaral
- Richmond, VA4 pag-aaral
- Winston-Salem, NC4 pag-aaral
- Cedar Rapids, IA4 pag-aaral
- Louisville, KY4 pag-aaral
- Cincinnati, OH4 pag-aaral
- Indianapolis, IN4 pag-aaral
- Tampa, FL4 pag-aaral
- Portland, OR4 pag-aaral
- Jacksonville, FL4 pag-aaral
- Charlottesville, VA3 pag-aaral
Ayos sa estado
- Arizona5 pag-aaral
- California20 pag-aaral
- Colorado11 pag-aaral
- Connecticut6 pag-aaral
- District of Columbia3 pag-aaral
- Florida15 pag-aaral
- Georgia7 pag-aaral
- Illinois12 pag-aaral
- Indiana5 pag-aaral
- Iowa6 pag-aaral
- Kansas9 pag-aaral
- Kentucky4 pag-aaral
- Maryland7 pag-aaral
- Massachusetts8 pag-aaral
- Michigan7 pag-aaral
- Minnesota12 pag-aaral
- Missouri5 pag-aaral
- Nebraska5 pag-aaral
- New Jersey9 pag-aaral
- New York21 pag-aaral
- North Carolina11 pag-aaral
- Ohio16 pag-aaral
- Oregon5 pag-aaral
- Pennsylvania16 pag-aaral
- Tennessee13 pag-aaral
- Texas26 pag-aaral
- Utah7 pag-aaral
- Virginia8 pag-aaral
- Washington10 pag-aaral
- Wisconsin10 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06350318A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07439653A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06742996Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Nagre-recruitPhase 2
Edad 60 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06052826A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06213311A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05615636A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Nagre-recruitPhase 1
Edad 0 hanggang 18 · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Nagre-recruitPhase 1/2
31 Days – 30 Years · Lahat ng kasarian · Na-update Set 14, 2026 · NCT04544592Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06634589Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT05272384Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06564038A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT06393738Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Nagre-recruitObservasyonal na pag-aaral
Edad 4 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07652580Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07520006A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07123454A Study of ARC-02 in B-cell NHL
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07691606Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05389423Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT07220616Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT04792502A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776Mula sa ClinicalTrials.gov, na-kuha noong Set 29, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.